Merus Completes Genmab Acquisition and Delists From Nasdaq

Merus ( (MRUS) ) has provided an update.

On September 29, 2025, Merus N.V. entered into a transaction agreement under which Genmab A/S, through its Dutch subsidiary Genmab Holding II B.V., launched a cash tender offer to acquire all issued and outstanding Merus common shares for $97.00 per share. The offer, which expired on December 11, 2025, resulted in 71,463,077 shares, or about 94.2% of the company’s share capital, being validly tendered, satisfying the minimum tender condition, with payment for these shares made on December 12, 2025. A subsequent offering period running until December 29, 2025 lifted total tenders to 73,884,293 shares, representing approximately 97.39% of Merus’s total share capital, after which Genmab and its subsidiary completed a back-end merger and cancellation effective the evening of December 29, 2025 (New York time), converting all remaining minority-held shares into the right to receive the same cash consideration, subject to Dutch dividend withholding tax of $10.67 per cancelled share. Following completion of these back-end transactions, no Merus common shares remained outstanding, Nasdaq was notified, trading was halted on the evening of December 29, 2025, and the shares ceased trading prior to the market open on December 30, 2025 as the company began delisting and deregistration steps, while two directors, Maxine Gowen and Anand Mehra, simultaneously stepped down from the board, marking Merus’s transition to a privately held entity under Genmab’s control and effectively ending its public reporting obligations.

The most recent analyst rating on (MRUS) stock is a Hold with a $97.00 price target. To see the full list of analyst forecasts on Merus stock, see the MRUS Stock Forecast page.

Spark’s Take on MRUS Stock

According to Spark, TipRanks’ AI Analyst, MRUS is a Neutral.

Merus’s overall stock score is primarily impacted by its weak financial performance, characterized by declining revenue and substantial losses. While technical analysis indicates strong upward momentum, the overbought signals suggest caution. The negative P/E ratio further reflects the company’s financial struggles, limiting its valuation appeal.

To see Spark’s full report on MRUS stock, click here.

More about Merus

Merus N.V. is a Netherlands-based public limited liability company operating in the biopharmaceutical sector, with its shares previously listed on the Nasdaq Stock Market in the form of common stock with a nominal value of €0.09 per share.

Average Trading Volume: 1,922,272

Technical Sentiment Signal: Buy

Current Market Cap: $7.35B

See more data about MRUS stock on TipRanks’ Stock Analysis page.